Monday, November 9, 2026

USD/CHF Bullish By 2% In The Last 10 Sessions

ViaNews Editorial Team

January 23, 2024

USD/CHF Bullish By 2% In The Last 10 Sessions

(VIANEWS) - USD/CHF (USDCHF) has been up by 2.26% for the last 10 sessions. At 03:07 EST on Tuesday, 23 January, USD/CHF (USDCHF) is $0.87.

USD/CHF's yearly highs and lows, it's 4.094% up from its 52-week low and 8.146% down from its 52-week high.

Volatility

USD/CHF's last week, last month's, and last quarter's current intraday variation average was 0.37%, 0.05%, and 0.33%, respectively.

USD/CHF's highest amplitude of average volatility was 0.37% (last week), 0.31% (last month), and 0.33% (last quarter), respectively.

Forex Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, USD/CHF's Forex is considered to be oversold (<=20).

News about

  • Eur/usd price analysis: hovers above 1.0900 followed by the 23.6% fibonacci level. According to FXStreet on Monday, 22 January, "If the EUR/USD pair surpasses the latter, it could approach the major level at 1.0950 followed by the 38.2% Fibonacci retracement level at 1.0957.", "Additionally, the trend-following momentum indicator suggests a confirmation of the bearish trend in the EUR/USD pair as the "Moving Average Convergence Divergence (MACD)" line lies below the centreline and shows a divergence below the signal line."
  • Eur/usd: further downside potential based on the poor economic performance of the eurozone – rabobank. According to FXStreet on Monday, 22 January, "We continue to see risk of EUR/USD pushing lower to 1.0500 on a three-month view."
  • Eur/usd set to trade out something like a 1.0850-1.0960 range near term – ING. According to FXStreet on Monday, 22 January, "Our baseline view sees EUR/USD hanging around these 1.0900 levels as the ECB tries to re-position for a data-dependent approach for future policy."
  • Eur/usd drifts lower as markets gear up for central bank rate call week. According to FXStreet on Monday, 22 January, "Despite bids getting caught up in a near-term congestion pattern, the EUR/USD is notably bullish in the medium-term, with a pattern of higher lows remaining intact and December's swing high into 1.1140 keeping the major pair on the high end.", "The EUR/USD continues to trade into the south end of the 200-hour Simple Moving Average (SMA), slumping below the 1.0900 handle after a brief test above the barrier early Monday."
  • Eur/usd lacks any firm near-term direction, oscillates in a range below 1.0900. According to FXStreet on Tuesday, 23 January, "In the meantime, diminishing odds for an early interest rate cut by the Federal Reserve (Fed) continue to act as a tailwind for the US Dollar (USD) and act as a headwind for the EUR/USD pair. ", "The EUR/USD pair struggles to gain any meaningful traction during the Asian session on Tuesday and oscillates in a narrow trading band below the 1.0900 round-figure mark. "

More news about USD/CHF (USDCHF).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Season: Regulatory Deadlines and Data Readouts Against Cost Discipline and Slipping Timelines
From late October 2026 to January 2027, mid-cap biotechs cluster pivotal data presentations (ESMO, AHA, AASLD), FDA decision dates (ivonescimab BLA on 2026-11-14, lorundrostat on 2026-12-22) and Q3 earnings. Alongside these, several companies are managing capital: lowering R&D and SG&A guidance, pushing clinical milestones into 2027, authorizing a $400M buyback, and pursuing a delisting. Late-stage programs in oncology, hepatitis delta, hypertension and women's health look near commercial inflection, while cost cuts and delays point to uneven balance-sheet strength.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,996
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,996 facts checked against source5,552 source documents archived
Query this data → isubstrate.com